The economic cost of obesity is expected to soar to $4 trillion by 2035. Weight loss drugs like Ozempic could change that, Goldman Sachs says.

• The rise in obesity is having a massive impact on the global economy, according to Goldman Sachs.
• The bank estimates that obesity will drag down the world's GDP by $4 trillion in 2035.
• But a new class of weight-loss drugs could change all of that, and represents a big opportunity for investors.

Obesity is prevalent throughout the US, and that's having a massive impact on the economy, according to Goldman Sachs.

The bank estimates that obesity is costing the US healthcare system $170 billion per year. And by 2035, Goldman Sachs estimates that the consequences of the chronic health condition will drag down global GDP by $4 trillion.

That's equivalent to Germany's GDP in 2022, making it the world's fourth-largest economy.